BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.

Mario MandalàGiuseppe PalmieriVienna LudoviniSara BaglivoFrancesca MarasciuloFrancesca CastiglioneAlessio GiliSimona Osella AbateMarco RubattoRebecca SenettaGianluca AvalloneSimone RiberoLuca RomanoNicola PimpinelliVincenzo De GiorgiFausto RoilaMarina PisanoMilena CasulaAntonella MancaMaria Cristina SiniDaniela MassiPietro Quaglinonull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

High VAF is an independent poor prognostic factor in MMP receiving BRAFi and MEKi. High VAF and BRAF amplification coexist in 7-11% of patients.

Keyphrases

prognostic factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
nucleic acid
wild type
signaling pathway
cell migration